Continuing its mission to expand access to essential treatments, Camber Pharmaceuticals introduces Abacavir and Lamivudine Tablets, USP [a-BAK-a-veer-and-la-MIV-yoo-deen] to its portfolio.
Abacavir/Lamivudine Tablets, USP are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Camber’s Abacavir and Lamivudine Tablets, USP (600 mg/300 mg) are supplied in bottles of 30 tablets.
To learn more about this product, visit: www.camberpharma.com/abacavir-lamivudine
